JP2021513851A5 - - Google Patents

Info

Publication number
JP2021513851A5
JP2021513851A5 JP2020543576A JP2020543576A JP2021513851A5 JP 2021513851 A5 JP2021513851 A5 JP 2021513851A5 JP 2020543576 A JP2020543576 A JP 2020543576A JP 2020543576 A JP2020543576 A JP 2020543576A JP 2021513851 A5 JP2021513851 A5 JP 2021513851A5
Authority
JP
Japan
Prior art keywords
antisense oligonucleotide
oligonucleotide according
seq
nucleic acid
atp7b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020543576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018076 external-priority patent/WO2019161105A1/en
Publication of JP2021513851A publication Critical patent/JP2021513851A/ja
Publication of JP2021513851A5 publication Critical patent/JP2021513851A5/ja
Withdrawn legal-status Critical Current

Links

JP2020543576A 2018-02-14 2019-02-14 ウィルソン病に対するオリゴヌクレオチド療法 Withdrawn JP2021513851A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630565P 2018-02-14 2018-02-14
US62/630,565 2018-02-14
PCT/US2019/018076 WO2019161105A1 (en) 2018-02-14 2019-02-14 Oligonucleotide therapy for wilson disease

Publications (2)

Publication Number Publication Date
JP2021513851A JP2021513851A (ja) 2021-06-03
JP2021513851A5 true JP2021513851A5 (cg-RX-API-DMAC7.html) 2022-02-22

Family

ID=67619598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543576A Withdrawn JP2021513851A (ja) 2018-02-14 2019-02-14 ウィルソン病に対するオリゴヌクレオチド療法

Country Status (15)

Country Link
US (1) US11578327B2 (cg-RX-API-DMAC7.html)
EP (1) EP3752614A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021513851A (cg-RX-API-DMAC7.html)
KR (1) KR20200120675A (cg-RX-API-DMAC7.html)
CN (1) CN112041439A (cg-RX-API-DMAC7.html)
AU (1) AU2019222767A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020016524A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090517A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002100A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020010226A2 (cg-RX-API-DMAC7.html)
IL (1) IL276701A (cg-RX-API-DMAC7.html)
MX (1) MX2020008533A (cg-RX-API-DMAC7.html)
PH (1) PH12020551219A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007644PA (cg-RX-API-DMAC7.html)
WO (1) WO2019161105A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025110984A1 (en) * 2023-11-21 2025-05-30 Hydrogene Therapeutics, Inc. Compositions and methods for treating wilson's disease
CN117925624B (zh) * 2024-03-22 2024-05-31 上海凌医生物科技有限公司 一种金属响应调控元件

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5578493A (en) * 1993-09-01 1996-11-26 The Trustees Of Columbia University In The City Of New York Wilson's disease gene
CA2108927C (en) 1993-09-21 2008-09-02 Peter Bull Wilson disease gene
TW520293B (en) 1995-11-22 2003-02-11 Univ Johns Hopkins Med Delivery system to enhance cellular uptake of biomolecules
US20040101854A1 (en) * 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of BCL2-associated athanogene expression
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20030180953A1 (en) 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
US20040126761A1 (en) * 2002-12-10 2004-07-01 Isis Pharmaceuticals Inc. Modulation of alpha-methylacyl-CoA racemase expression
WO2004035819A2 (en) 2002-10-21 2004-04-29 Exiqon A/S Oligonucleotide analogues for detecting and analyzing nucleic acids
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
EP1718741A2 (en) * 2004-01-29 2006-11-08 Cellzome Ag Treatment of neurodegenerative diseases by the use of atp7a
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
US20070048756A1 (en) 2005-04-18 2007-03-01 Affymetrix, Inc. Methods for whole genome association studies
EP1783645A1 (en) * 2005-11-08 2007-05-09 Actigenics Methods for the identification of microRNA and their applications in research and human health
US8178503B2 (en) 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
JP4841279B2 (ja) 2006-03-23 2011-12-21 一般財団法人 化学物質評価研究機構 被検物質の発がん性予測方法
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
BR112014016870A2 (pt) * 2012-01-09 2017-06-27 Huesken Dieter composições orgânicas para tratar doenças relacionadas com beta-catenina
WO2014036301A1 (en) * 2012-08-30 2014-03-06 Isis Pharmaceuticals, Inc. Modulation of copper related diseases by ctr1
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
US20160258005A1 (en) * 2013-07-02 2016-09-08 The Trustees Of The University Of Pennsylvania Methods for rapid ribonucleic acid fluorescence in situ hybridization
CN106061981A (zh) 2013-11-06 2016-10-26 索尔斯蒂斯生物有限公司 具有二硫化物基团的多核苷酸构建体
CN107109405A (zh) 2014-06-06 2017-08-29 索尔斯蒂斯生物有限公司 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
EP3164420A4 (en) 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
AU2015346042A1 (en) 2014-11-14 2017-04-27 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of proteins
US20180002379A1 (en) 2015-01-21 2018-01-04 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
CN105986015B (zh) * 2015-02-05 2020-10-23 大连晶泰生物技术有限公司 一种基于高通量测序的多样本的一个或多个靶序列的检测方法和试剂盒
EP3286318A2 (en) 2015-04-22 2018-02-28 Mina Therapeutics Limited Sarna compositions and methods of use
EP3386517A4 (en) 2015-12-08 2019-08-07 Solstice Biologics, Ltd. POLYNUCLEOTIDE CONSTRUCTS COMPRISING AN AUXILIARY FRACTION RELATED NON-BIOREVERSIBLE TO AN INTERNETOSIDIC PHOSPHATE OR PHOSPHOROTHIOATE
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106283A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of liver diseases
KR101743211B1 (ko) 2016-06-24 2017-06-15 주식회사 녹십자지놈 선천성 기능장애 진단용 조성물 및 이의 용도
CA3107890A1 (en) * 2018-08-21 2020-02-27 Deep Genomics Incorporated Therapeutic splice-switching oligonucleotides
IL308353A (en) * 2021-05-10 2024-01-01 Entrada Therapeutics Inc Compositions and methods for modulating tissue distribution of intracellular therapies
WO2022256283A2 (en) * 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar

Similar Documents

Publication Publication Date Title
JP7379387B2 (ja) Atxn2発現を制御するためのオリゴヌクレオチド
CN108271351B (zh) 用于调节血管紧张素原表达的化合物和方法
JP2024056820A (ja) Scn9a発現を調節するためのオリゴヌクレオチド
JP2024105284A5 (cg-RX-API-DMAC7.html)
JP2016513976A5 (cg-RX-API-DMAC7.html)
JP2018519811A5 (cg-RX-API-DMAC7.html)
JP2012147790A (ja) エキソンスキッピングを誘発する為の手段及び方法
CA2453301A1 (en) Synthetic double-stranded oligonucleotides for specific inhibition of gene expression
CN107406852A (zh) 用于莱伯氏先天性黑蒙的寡核苷酸疗法
WO2000061810A1 (en) Antisense oligonucleotides comprising universal and/or degenerate bases
JP2023503635A (ja) Rna分子を合成する方法
CA3072314A1 (en) Nucleic acid molecule for reduction of papd5 and papd7 mrna for treating hepatitis b infection
JP7499267B2 (ja) Atxn2発現を調節するためのオリゴヌクレオチド
CN114901821A (zh) Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
JP2026074094A (ja) Fubp1発現を調節するための増強されたオリゴヌクレオチド
TW202329983A (zh) Rna編輯
CN115698290A (zh) 用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法
EP2175023A1 (en) Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA
CN115551519A (zh) 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
CN114829601A (zh) Sbds抑制剂用于治疗乙型肝炎病毒感染的用途
TW202136510A (zh) 用於抑制scn9a表現之增強型寡核苷酸
WO2020038971A1 (en) Antisense oligonucleotides targeting vcan
CN115605592A (zh) 用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法
JP2025522625A5 (cg-RX-API-DMAC7.html)
HK40110327A (en) Asymmetric short duplex dna as a novel gene silencing technology and use thereof